



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **GENEGO INC. INTEGRATES ACCELRY'S ACCORD TECHNOLOGY IN METADRUG™**

**St. Joseph, Michigan, June 6th, 2005**-GeneGo Inc., a leading provider of databases and software for systems biology, announced today that they have integrated Accelrys' Accord technology in MetaDrug™, their Systems-ADME/Tox and medicinal chemistry platform .

**MetaDrug™** features maps, pathways and networks for human proteins related to ADME/TOX; a database of small molecules with kinetic data for human drug metabolizing enzymes, Proprietary algorithms for rule-based metabolite prediction, highlighting of reactive metabolites, >40 QSAR models for ADME/TOX properties, descriptors relevant to ADME parsers for importing data from all major microarray platforms, SAGE, proteomics and metabolomics data; two proprietary network building algorithms; flexible visualization and data exchange tools.

**MetaCore™** features a comprehensive set of maps, pathways and networks for almost all known human proteins; parsers for importing data from all major microarray platforms, SAGE, aCGH, RNAi proteomics and metabolomics data; seven proprietary network building algorithms; flexible visualization and data exchange tools.

“Integrating Accelrys' Accord technology with GeneGo's MetaDrug, is another example of how Accelrys is looking to expand access to best-of-breed technologies to scientists in the Pharmaceutical and Biotech sector,” commented Dr. Eric Jamois, Director of Business Development at Accelrys. “Combining the power of the Accord Chemistry engine with MetaDrug's algorithms will ultimately help enhance the data visualization and database searching capabilities of MetaDrug.”

“We are thrilled to be working with Accelrys and excited about the capabilities of our combined software for the field of Systems-ADME/Tox.” said Dr. Sean Ekins, Vice President, Computational Biology at GeneGo. “It took our team several years to build tools and pathway content, proprietary algorithms for metabolite prediction and

ADME/Tox QSAR models. We can now apply the Accord tools for molecule visualization and database searching capabilities within MetaDrug™.”

### **About GeneGo**

GeneGo is a Michigan-based company developing systems biology technology for life science research. The Company’s original computational platform MetaCore allows an integration and analysis of different kinds of high throughput experimental data (mRNA expression, proteomics, metabolites, phenotypic data etc.) and relevant active chemistry (metabolites, drugs, other xenobiotics) within the framework of biological pathways and networks. GeneGo’s first product, MetaCore™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. GeneGo’s second product, MetaDrug™ is a pioneering Systems-ADME/TOX platform which combines software for predicting metabolites and over 40 ADME/Tox properties with visualization and analysis of toxicogenomics and metabolomics data. MetaDrug™ can be used as a stand alone product or together with MetaCore™, GeneGo’s flagship analytical platform. MetaDrug™, is designed for medicinal chemists, computational chemists, bioanalytical, drug disposition and toxicology scientists and enables prediction of metabolites and their likely toxicity in humans.

For more information, please visit the company's Web site at [www.genego.com](http://www.genego.com) .

**MetaCore™, MetaBase™ and MetaDrug™** are trademarks of GeneGo, Inc.

### **About Accelrys, Inc**

Accelrys, Inc. is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California. For more information about Accelrys, visit its website at <http://www.accelrys.com/>.